TY - JOUR
T1 - Development and evaluation of a bladder Cancer specific survivorship care plan by patients and clinical care providers
T2 - A multi-methods approach
AU - Lee, Cheryl T.
AU - Mohamed, Nihal E.
AU - Pisipati, Sailaja
AU - Shah, Qainat N.
AU - Agarwal, Piyush K.
AU - Downs, Tracy M.
AU - Droller, Michael
AU - Gilbert, Scott M.
AU - Goltz, Heather H.
AU - Hall, Simon J.
AU - Hendawi, Mohamed
AU - Hoffman-Censits, Jean
AU - O'Donnell, Michael
AU - Kaag, Matthew
AU - Karsh, Lawrence I.
AU - Kassouf, Wassim
AU - Quale, Diane Z.
AU - Sagalowsky, Arthur
AU - Steinberg, Gary D.
AU - Latini, David M.
N1 - Funding Information:
Authors SP, QNS, PKA, TMD, MD, SMG, HHG, MH, MOD, MK, WK, DZQ, AS, GDS, DML declare that they have no conflicts of interest. CTL received a research grant from MelRite and is a consultant with Merck. She has no conflicts related to the content of this manuscript. NEM received research grants from The National Institute of Health and The American Cancer Society. She received an honorarium for participating in the Incyte Bladder Cancer Advisory Board. SH received a research grant from National Cancer Institute. JHC received research funding from Genetech/Roche and is a consultant with Astra-Zeneca, Genetech/Roche, Foundation Medicine. She has no conflicts related to the content of this manuscript. LIK received research funding from Astellas, Allergan, AstraZeneca, Augmenix, Bayer, BioXcel, CU Optics, CUSP Lancelot, Dendreon, Exact Sciences, Ferring, FKD, Genetech/Roche, GenomeDx, Genomic Health, Janssen, Merck, Myovant, Nucleix, Pfizer, Pharmtech/Veru, Precision Biopsy, Precision Med, Siemens, Spectrum, Urogen, Vaxiion. He is a Consultant / Advisory for 3D Biopsy, Abbvie, Astellas, Astra-Zeneca, Augmenix, Bayer, Den-dreon, Ferring, Janssen, Pfizer, Precision Biopsy, Spectrum, Vaxiion. He is a speaker for Amgen, Astellas, Bayer, Janssen, Pfizer and is the owner of Swan Valley Medical. He has no conflicts related to the content of this manuscript.
PY - 2020/7/24
Y1 - 2020/7/24
N2 - Background, context and purpose: In spite of the mixed evidence for their impact, survivorship Care Plans (SCPs) are recommended to enhance quality of care for cancer survivors. Data on the feasibility of SCPs in bladder cancer (BC) is sparse. Using a mixed-methods approach, this study describes the iterative development, acceptability and feasibility of BC specific SCP (BC-SCP) in clinical settings. Methods: In Phase I, we developed the BC-SCP. In Phase II, we conducted four focus groups with 19 patients and 15 providers to examine its acceptability and usability challenges. Data analyses using the Atlas.ti program, informed refinement of the BC-SCP. In Phase III, we conducted feasibility testing of the refined BC-SCP with 18 providers from 12 health-centers. An encounter survey was completed after each assessment to examine the feasibility of the BC-SCP. Chi-square and Fisher Exact tests were used for comparative analyses. Results: During phase I, we observed high patient and provider acceptability of the BC-SCP and substantial engagement in improving its content, design, and structure. In Phase II, providers completed 59 BC-SCPs. Mean time for BC-SCP completion was 12.3 min. Providers reported that BC-SCP content was clear, did not hamper clinic flow and was readily completed with easy-to-access information. Comparative analyses to examine differences in SCP completion time by patient clinico-demographic characteristics and provider type revealed no significant differences. Conclusions: Our BC-SCP has clinical relevance, and can be used in an active practice setting. However, considerable progress will be necessary to achieve implementation of and sharing the BC-SCP with patients and care providers, particularly within the electronic medical record. In summary, BC-SCPs are essential to improve the follow up care of BC survivors. Clinical resources are required to ensure appropriate implementation of BC-SCPs. Trial registration: Study HUM00056082.
AB - Background, context and purpose: In spite of the mixed evidence for their impact, survivorship Care Plans (SCPs) are recommended to enhance quality of care for cancer survivors. Data on the feasibility of SCPs in bladder cancer (BC) is sparse. Using a mixed-methods approach, this study describes the iterative development, acceptability and feasibility of BC specific SCP (BC-SCP) in clinical settings. Methods: In Phase I, we developed the BC-SCP. In Phase II, we conducted four focus groups with 19 patients and 15 providers to examine its acceptability and usability challenges. Data analyses using the Atlas.ti program, informed refinement of the BC-SCP. In Phase III, we conducted feasibility testing of the refined BC-SCP with 18 providers from 12 health-centers. An encounter survey was completed after each assessment to examine the feasibility of the BC-SCP. Chi-square and Fisher Exact tests were used for comparative analyses. Results: During phase I, we observed high patient and provider acceptability of the BC-SCP and substantial engagement in improving its content, design, and structure. In Phase II, providers completed 59 BC-SCPs. Mean time for BC-SCP completion was 12.3 min. Providers reported that BC-SCP content was clear, did not hamper clinic flow and was readily completed with easy-to-access information. Comparative analyses to examine differences in SCP completion time by patient clinico-demographic characteristics and provider type revealed no significant differences. Conclusions: Our BC-SCP has clinical relevance, and can be used in an active practice setting. However, considerable progress will be necessary to achieve implementation of and sharing the BC-SCP with patients and care providers, particularly within the electronic medical record. In summary, BC-SCPs are essential to improve the follow up care of BC survivors. Clinical resources are required to ensure appropriate implementation of BC-SCPs. Trial registration: Study HUM00056082.
UR - http://www.scopus.com/inward/record.url?scp=85088680090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088680090&partnerID=8YFLogxK
U2 - 10.1186/s12913-020-05533-7
DO - 10.1186/s12913-020-05533-7
M3 - Article
C2 - 32709234
AN - SCOPUS:85088680090
VL - 20
JO - BMC Health Services Research
JF - BMC Health Services Research
SN - 1472-6963
IS - 1
M1 - 686
ER -